Teva Pharmaceutical, Abbvie's Allergan Settle Opioid Suit With San Francisco -- Update
July 12 2022 - 12:39PM
Dow Jones News
By Will Feuer
Teva Pharmaceutical Industries Ltd. and Abbvie Inc.'s Allergan
unit reached an agreement with the city and county of San Francisco
that settles claims that the companies fueled a surge of
opioid-related addiction and overdose in San Francisco, San
Francisco City Attorney David Chiu said.
The settlement provides San Francisco with $34 million in cash
payments, in addition to some $20 million worth of Narcan, a
medicine used to treat opioid overdoses in emergency situations,
Mr. Chiu said.
In a separate release, Teva said the agreement is not an
admission of liability or wrongdoing, adding that it will continue
to pursue a nationwide settlement.
Late last year, a Superior Court judge in California found that
Teva did not cause a public nuisance in Orange County, Los Angeles
County, Santa Clara County and the City of Oakland, nor wrongfully
promote opioid products in the state, the company noted.
A representative for Allergan said the company has agreed to pay
about $12.9 million to address opioid-related issues and reimburse
attorneys' fees as part of the agreement. "Allergan previously made
the decision to voluntarily discontinue its branded prescription
opioid business, which had a minimal market share of less than 1%
of nationwide prescriptions," Allergan said.
Tuesday's agreement severs Allergan and Teva from San
Francisco's ongoing trial, Mr. Chiu said, and closing arguments
against the remaining defendant, Walgreens Boots Alliance Inc.,
begin later Tuesday.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
July 12, 2022 12:24 ET (16:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024